Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression

4 Aug 2009

Abstract excerpt

Multiple myeloma (MM) is a cancer of plasma cells with complex molecular characteristics that evolves from monoclonal gammopathy of undetermined significance, a highly prevalent premalignant condition. MM is the second most frequent hematologic cancer in the United States, and it remains incurable, thereby highlighting the need for new therapeutic approaches, particularly those targeting common molecular pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Microtubule and mitosis dynamics
Share to Multiple Myeloma Research and Treatments
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19652203
DOI: 10.1182/blood-2008-12-194290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progressionPMID 19652203Read ↗

Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway.Semantic proximity Read ↗

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelSemantic proximity Read ↗

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaSemantic proximity Read ↗

Advances in biology of multiple myeloma: clinical applicationsSemantic proximity Read ↗

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaSemantic proximity Read ↗

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive diseaseSemantic proximity Read ↗

Bruton’s Tyrosine Kinase Targeting in Multiple MyelomaSemantic proximity Read ↗

From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.Semantic proximity Read ↗

Myeloma cell–derived Runx2 promotes myeloma progression in boneSemantic proximity Read ↗

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic targetSemantic proximity Read ↗

Identification of biomarkers and candidate regulators for multiple myeloma under the knockout of AURKASemantic proximity Read ↗

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.